Read More Pharma Industry News Rallybio Phase 2 trial of RLYB212 begins to tackle FNAIT in high-risk pregnancies Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company known for advancing innovative therapies for rare diseases, has commenced… byPallavi MadhirajuNovember 23, 2024